MDT-AP-1276
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 32.04
- os_event
- false
- age_years
- 4
- sex
- M
- new_clusters
- S1
- umap1_2d
- -1.864948697
- umap2_2d
- -10.70749578
- umap1_3d
- -1.501494795
- umap2_3d
- -1.240714391
- umap3_3d
- 3.937708831
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.440
- PANCREAS_BETA_CELLS+0.360
- APICAL_SURFACE+0.220
- SPERMATOGENESIS+0.180
- ESTROGEN_RESPONSE_LATE+0.140
- MYOGENESIS+0.110
- INFLAMMATORY_RESPONSE+0.040
- ESTROGEN_RESPONSE_EARLY+0.030
- TNFA_SIGNALING_VIA_NFKB-0.030
- COAGULATION-0.050
Top 10 suppressed
- PROTEIN_SECRETION-0.620
- OXIDATIVE_PHOSPHORYLATION-0.510
- UNFOLDED_PROTEIN_RESPONSE-0.480
- MYC_TARGETS_V1-0.440
- TGF_BETA_SIGNALING-0.440
- ADIPOGENESIS-0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.420
- MTORC1_SIGNALING-0.400
- DNA_REPAIR-0.390
- HEME_METABOLISM-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1164 | — | — | 0.925 |
| 2 | BS_23W9EPFE | Ganglioglioma | — | 0.924 |
| 3 | SRR1320342 | GTEX | — | 0.920 |
| 4 | SRR1366141 | GTEX | — | 0.918 |
| 5 | TCGA-DK-A1A7-01A-11R-A13Y-07 | — | — | 0.917 |
| 6 | MNG598 | — | — | 0.917 |
| 7 | SRR1417111 | GTEX | — | 0.916 |
| 8 | MNG597 | — | — | 0.914 |
| 9 | MNG1118 | — | — | 0.913 |
| 10 | MDT-AP-0706 | Med | Medulloblastoma | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.440 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.040 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.030 | Inavolisib | — uncovered |